Top ▲
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | - | 223 | 1q23.2 | APCS | amyloid P component, serum | 3-4 |
| Mouse | - | 224 | 1 80.33 cM | Apcs | amyloid P component, serum | |
| Rat | - | 228 | 13q24 | Apcs | amyloid P component, serum | |
| Gene and Protein Information Comments | ||||||
| The human protein has a signal peptide (1-19) with a mature peptide chain of 204 amino acids (20-223). | ||||||
| Previous and Unofficial Names |
| serum amyloid P-component | amyloid P component | pentraxin-2 | pentraxin 2 | PTX2 | SAP |
| Database Links |
|
| Alphafold | P02743 (Hs), P12246 (Mm), P23680 (Rn) |
| ChEMBL Target | CHEMBL4929 (Hs) |
| Ensembl Gene | ENSG00000132703 (Hs), ENSMUSG00000026542 (Mm), ENSRNOG00000009086 (Rn) |
| Entrez Gene | 325 (Hs), 20219 (Mm), 29339 (Rn) |
| Human Protein Atlas | ENSG00000132703 (Hs) |
| KEGG Gene | hsa:325 (Hs), mmu:20219 (Mm), rno:29339 (Rn) |
| OMIM | 104770 (Hs) |
| Pharos | P02743 (Hs) |
| RefSeq Nucleotide | NM_001639 (Hs), NM_011318 (Mm), NM_017170 (Rn) |
| RefSeq Protein | NP_001630 (Hs), NP_035448 (Mm), NP_058866 (Rn) |
| SynPHARM | 81894 (in complex with CPHPC) |
| UniProtKB | P02743 (Hs), P12246 (Mm), P23680 (Rn) |
| Wikipedia | APCS (Hs) |
Download all structure-activity data for this target as a CSV file 
| Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| Serum amyloid P or pentraxin 2 is a multi-function circulating plasma protein. It exhibits activity as a soluble pattern recognition receptor of the innate immune system, that can bind DNA and histones when these are released from damaged cells. A recombinant form of human pentraxin 2 (PRM-151; Promedior) has been reported as an anti-fibrotic immunomodulator [2]. PRM-151 was found to inhibit the differentiation of circulating monocytes into fibrocytes and profibrotic macrophages, with an associated anti-fibrotic effect in a preclinical model of opacity-producing corneal injury [6]. In humans PRM-151 has demonstrated clinical utility in patents with idiopathic pulmonary fibrosis (IPF; see Phase 2 trial NCT02550873) [5]. The anti-fibrotic efficacy of PRM-151 is also being evaluated in patients with myelofibrosis, and as a mechanism to reduce scarring post-trabeculectomy in gluacoma patients. Click here to link to ClinicalTrials.gov's full list of PRM-151 studies. |
| Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
1. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ et al.. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 468 (7320): 93-7. [PMID:20962779]
2. Duffield JS, Lupher Jr ML. (2010) PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect, 23 (5): 305-15. [PMID:20603654]
3. Mantzouranis EC, Dowton SB, Whitehead AS, Edge MD, Bruns GA, Colten HR. (1985) Human serum amyloid P component. cDNA isolation, complete sequence of pre-serum amyloid P component, and localization of the gene to chromosome 1. J Biol Chem, 260 (12): 7752-6. [PMID:2987268]
4. Ohnishi S, Maeda S, Shimada K, Arao T. (1986) Isolation and characterization of the complete complementary and genomic DNA sequences of human serum amyloid P component. J Biochem, 100 (4): 849-58. [PMID:3029048]
5. Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE et al.. (2019) Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med, 7 (8): 657-664. [PMID:31122893]
6. Santhiago MR, Singh V, Barbosa FL, Agrawal V, Wilson SE. (2011) Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbits. Exp Eye Res, 93 (5): 786-9. [PMID:21933674]
7. Wermuth CG. (2004) Selective optimization of side activities: another way for drug discovery. J Med Chem, 47 (6): 1303-14. [PMID:14998318]
Serum pentraxins: amyloid P component, serum. Last modified on 11/02/2020. Accessed on 05/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2839.
target has curated data in GtoImmuPdb
